Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486900 | 0.88 | HDAC1 (0.53) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL725280 | 0.87 | HDAC1 (0.52) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL1486959 | 0.85 | HDAC1 (0.66) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL12473984 | 0.84 | HDAC1 (0.83) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL1486946 | 0.78 | HDAC1 (0.80) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL1486943 | 0.78 | HDAC1 (0.80) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL722453 | 0.76 | HDAC1 (0.77) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL725551 | 0.76 | HDAC1 (0.77) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL725420 | 0.74 | HDAC1 (1.00) | HDAC1KCNH2HDAC3HDAC4HDAC2 | |
| SCHEMBL721805 | 0.74 | HDAC1 (1.00) | HDAC1KCNH2HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012025155-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025155-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885KCNH2 3415/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.